McKesson (MCK) DIvidends Date & History

Key Takeaways

• McKesson offers a current dividend yield of 0.40%, with a quarterly payout of $0.82 per share (annualized $3.28).
• The company has raised its dividend for 17 consecutive years, reflecting a commitment to shareholder returns.
• Extremely low payout ratio of 8.83% ensures high sustainability, well-covered by earnings and free cash flow.
• Recent free cash flow exceeds $5 billion annually, providing ample coverage for dividends and buybacks.
• Yield trails peers like CAH (1.06%) and COR (0.75%), prioritizing growth over high income.

Dividend Overview

McKesson Corporation (MCK), a leading healthcare distribution and technology firm, maintains a modest dividend profile suited to growth-oriented investors. The current quarterly dividend stands at $0.82 per share, payable on July 1, 2026, to shareholders of record on June 1, 2026, with an ex-dividend date of June 1, 2026. This equates to an annualized dividend of $3.28 and a yield of 0.40%. Payments occur quarterly, historically in January, April, July, and October. While not a high-yield stock, McKesson qualifies as a dividend growth contender due to consistent raises and a low payout commitment, allowing reinvestment in its pharmaceutical distribution and oncology businesses. The policy emphasizes balanced capital returns via dividends and share repurchases.

Dividend History and Growth

McKesson has a robust history of dividend payments, with quarterly increases nearly every year for the past two decades. The payout has grown from $0.28 per share in 2016 to $0.82 today, delivering a five-year compound annual growth rate (CAGR) of approximately 11.7%. Notable recent hikes include a 15% jump from $0.71 to $0.82 in mid-2025 and prior shifts from $0.62 to $0.71 in early 2025. The company boasts 17 consecutive years of dividend growth, underscoring a long-term strategy of rewarding shareholders amid expanding operations in U.S. drug distribution. No cuts appear in recent history, reflecting operational stability.

Dividend Sustainability and Payout Ratio

McKesson's dividend is exceptionally sustainable, with a trailing payout ratio of 8.83%—far below the 60-75% threshold for caution. Earnings per share comfortably cover the payout, while fiscal 2025 free cash flow (FCF) reached $5.5 billion, dwarfing the roughly $450 million annual dividend obligation (based on outstanding shares). Fiscal 2026 shows continued strength, with $2.2 billion FCF in Q2 alone. Moderate debt levels and robust cash generation from its distribution network further bolster confidence. This conservative approach leaves room for future raises or buybacks without straining finances.

Dividend Compared to Industry Peers

In the pharmaceutical wholesale sector, McKesson's 0.40% yield lags peers but signals a growth focus. CAH (Cardinal Health) offers 1.06% with a 29-32% payout ratio, while COR (Cencora) yields 0.75% at around 28% payout. Both competitors pay higher relative to earnings, potentially limiting flexibility. McKesson's lower yield aligns with its strategy of aggressive repurchases ($3.1 billion in FY25) and reinvestment, making it attractive for total return seekers versus pure income plays. Sector averages hover higher, but MCK's safety stands out.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to streamline your research.

Is This Stock Attractive for Dividend Investors?

McKesson appeals to dividend growth investors prioritizing safety and long-term compounding over immediate high income. Its ultra-low payout ratio and 17-year raise streak suit conservative portfolios seeking reliable progression amid healthcare sector volatility. Those favoring total shareholder returns benefit from robust FCF supporting both dividends and substantial buybacks, enhancing yield on cost over time. However, yield hunters may look elsewhere, as the modest 0.40% trails high-yield alternatives. Long-term holders valuing earnings coverage and balance sheet strength—bolstered by dominant market share in drug distribution—find alignment, particularly if future raises accelerate with profitability gains. Balanced investors weighing growth potential against income will appreciate the profile, though it demands patience given the low starting yield.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations